ARCTURUS THERAPEUTICS HOLDIN (ARCT)

Company Profile

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The company is headquartered in San Diego, California and currently employs 180 full-time employees. The company went IPO on 2013-05-22. The firm is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. The company is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.

Company Info

ARCTURUS THERAPEUTICS HOLDIN

10628 Science Center Dr Ste 250

San Diego CALIFORNIA 92121

P: 18589002660

CEO: Joseph E. Payne

Employees: 180

Website: https://arcturusrx.com/